Table 1 Participant characteristics

From: Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome

A

Participant characteristics

DNA-seq

RNA-seq

SOC n = 30

DP n = 59

Total n = 89

P value

SOC n = 24

DP n = 46

Total n = 70

P value

Age (years): median (IQR)

39 (31–49)

38 (32–50)

38 (32–50)

0.86

39 (31–50)

40 (31–54)

39 (31–53)

0.58

Race/ethnicity

   

0.87

   

0.89

 Non-Hispanic White

14 (47%)

30 (51%)

44 (49%)

10 (42%)

24 (52%)

34 (49%)

 Hispanic White

4 (13%)

11 (19%)

15 (17%)

4 (17%)

9 (20%)

13 (19%)

 Asian/Pacific Islander

3 (10%)

7 (12%)

10 (11%)

2 (8%)

3 (7%)

5 (7%)

 Black/African American

2 (7%)

2 (3%)

4 (4%)

2 (8%)

2 (4%)

4 (6%)

 Multiracial/Other

6 (20%)

7 (12%)

13 (15%)

5 (21%)

6 (13%)

11 (16%)

 Unknown

1 (3%)

2 (3%)

3 (3%)

1 (4%)

2 (4%)

3 (4%)

Living with HIV infection

12 (40%)

23 (39%)

35 (39%)

0.93

9 (38%)

24 (52%)

33 (47%)

0.24

 Unknown CD4 count

4/12 (33%)

4/23 (17%)

8/35 (23%)

0.40

2/9 (22%)

5/24 (21%)

7/33 (21%)

1.00

 CD4 count (cells per mm3): median (IQR)

710 (398–790)

646 (524–807)

695 (495–807)

0.83

743 (508–984)

726 (577–850)

734 (562–896)

0.79

B

Month-6 participant characteristics

DNA-seq (n = 69 participants)

RNA-seq (n = 60 participants)

SOC n = 26

DP n = 43

P value

SOC n = 22

DP n = 38

P value

Doxycycline doses: median (IQR, range)

0 (0–7, 0–14)

42 (27–64, 0–200)

4.2 × 10−10

0 (0–7, 0–14)

42 (29–65, 0–200)

1.9 × 10−9

 0 doses

16 (62%)

3 (7%)

3.0 × 10−10

14 (64%)

2 (5%)

2.3 × 10−9

 1–25 doses

10 (38%)

8 (19%)

8 (36%)

7 (18%)

 26–50 doses

0 (0%)

15 (35%)

0 (0%)

15 (39%)

 >50 doses

0 (0%)

17 (40%)

0 (0%)

14 (37%)

Received non-doxycycline antibiotics since enrollment

15 (58%)

14 (33%)

5.2 × 10−7

13 (59%)

10 (26%)

7.1 × 10−10

 Cephalosporin

12 (46%)

10 (23%)

4.8 × 10−2

10 (45%)

8 (21%)

4.7 × 10−2

 Penicillin

3 (12%)

3 (7%)

0.67

3 (14%)

2 (5%)

0.35

 Clindamycin

0 (0%)

2 (5%)

0.52

0 (0%)

1 (3%)

1.00

 Azithromycin

0 (0%)

1 (2%)

1.00

1 (5%)

0 (0%)

0.37

 Quinolone

0 (0%)

1 (2%)

1.00

0 (0%)

1 (3%)

1.00

 Vancomycin

0 (0%)

1 (2%)

1.00

0 (0%)

1 (3%)

1.00

  1. A, Participant characteristics at time of enrollment by analyzable DNA-seq and RNA-seq samples. B, Participant characteristics for those with month-6 samples by DNA-seq and RNA-seq. Each doxycycline treatment day was equivalent to one doxycycline dose. Doxy-PEP dose was a one-time doxycycline dose of 200 mg. P values were calculated by Wilcoxon rank-sum test for age, CD4 count and number of doxycycline doses and by the chi-square test or Fisher’s exact test if count was less than 5 for all other variables.
Back to article page